Lenvatinib Mesylate Intermediate CAS 205448-65-3 Maʻemaʻe >98.0% (HPLC) Hale Hana

ʻO ka wehewehe pōkole:

Inoa Kemika: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate

CAS: 205448-65-3

Maʻemaʻe: >98.0% (HPLC)

'Ano: 'Oke-ke'oke'o i ka pauda melemele

Kūwaena o Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Na Waiwai Kemika:

Inoa Kimia Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate
Nā huaʻōlelo like 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Lenvatinib Intermediate 3
Helu CAS 205448-65-3
Helu CAT RF-PI1973
Kūlana Kūʻai Ma ka waihona, ka mana hana 50 MT / Makahiki
ʻĀpana Molekala C12H11NO4
Kaumaha Molecular 233.22
Lae paila 421.0±45.0℃
ʻO ka mānoanoa 1.267±0.060 g/cm3
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Pau-Keʻokeʻo a Melemele
Maʻemaʻe / Kaʻina Hanana >98.0% (HPLC)
Nalo ma ka maloo <1.00%
Koena ma ka Ignition <0.50%
Huina paumaele <2.00%
H-NMR Kūlike i ka hoʻolālā
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana Nā Kūwaena Lapaʻau

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai

Pono:

1

FAQ:

Noi:

ʻO Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) kahi mea waena o Lenvatinib Mesylate (CAS: 857890-39-2).ʻO Lenvatinib, i kūʻai ʻia ma lalo o ka inoa inoa ʻo Lenvima ma waena o nā mea ʻē aʻe, he lāʻau anti-cancer no ka mālama ʻana i kekahi ʻano maʻi maʻi thyroid a no nā maʻi maʻi ʻē aʻe pū kekahi.Ua hoʻomohala ʻia e Eisai Co. a hana ma ke ʻano he mea hoʻopaneʻe kinase lehulehu e kūʻē i nā kinase VEGFR1, VEGFR2 a me VEGFR3.Ua ʻae ʻia ʻo Lenvatinib (mai ka makahiki 2015) no ka mālama ʻana i ka maʻi maʻi thyroid ʻokoʻa i ʻike hou ʻia a i ʻole metastatic, holomua, a ʻaʻole i pane i ka mālama ʻana me ka iodine radioactive (radioiodine).Ma Mei 2016, ua ʻae ka US Food and Drug Administration (FDA) iā ia (i hui pū me everolimus) no ka mālama ʻana i ka maʻi maʻi maʻi maʻi renal cell ma hope o hoʻokahi lāʻau anti-angiogenic mua.Ua ʻae ʻia ka lāʻau lapaʻau i ka US a me ka European Union no ka maʻi hepatocellular carcinoma ʻaʻole hiki ke hoʻoneʻe ʻia i nā mea maʻi i loaʻa ʻole i ka maʻi maʻi maʻi ma ka waha a i ʻole ka injection.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou